Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial)
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial)
复制标题
DOI：
10.1002/ajh.24770
复制
发表时间：
2017-08-01
影响因子：
12.8
通讯作者：
DeBaun, Michael R.
中科院分区：
文献类型：
--
作者：
Galadanci, Najibah A.;Abdullahi, Shehu Umar;DeBaun, Michael R.
绝大多数患有镰状细胞性贫血（SCA）的儿童生活在非洲，那里缺乏基于证据的中风初级预防指南。在尼日利亚的卡诺，我们进行了一项可行性试验，以确定经颅多普勒（TCD）测量结果异常的儿童中使用羟基脲治疗作为一级预防卒中的可接受性。SCA和TCD非成像测量异常（200 cm/s）的儿童接受中等固定剂量的羟基脲治疗（约20 mg/kg/天）。TCD测量的儿童对照组
The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking. In Kano, Nigeria, we conducted a feasibility trial to determine the acceptability of hydroxyurea therapy for primary stroke prevention in children with abnormal transcranial Doppler (TCD) measurements. Children with SCA and abnormal non-imaging TCD measurements (200 cm/s) received moderate fixed-dose hydroxyurea therapy (approximate to 20 mg/kg/day). A comparison group of children with TCD measurements